BCL2 and cancer: By univariate survival analysis, Bcl-2 positivity was associated with a good outcome in cats with luminal FMC, in terms of disease-free interval (HR = 0.20, 95% CI: 0.09–0.46; p = 0.010; Fig. 3a), overall survival (HR = 0.36, 95%-CI: 0.20–0.67; p = 0.010; Fig. 3b), and cancer-specific survival (HR = 0.40, 95% CI: 0.20–0.82; p = 0.036; Fig. 3c).